Court of Justice of the European Communities (including Court of First Instance Decisions)

ORDER OF THE GENERAL COURT (Fifth Chamber)

22 December 2023 (*)

(Action for annulment – REACH – Establishment of a list of substances identified for eventual inclusion in Annex XIV to Regulation (EC) No 1907/2006 – Letter requesting that the Commission ask ECHA to re-examine the inclusion of phenanthrene on that list – The Commission’s refusal to make a request to ECHA to prepare a dossier in accordance with Annex XV to Regulation No 1907/2006 – Act not open to challenge – Inadmissibility)

In Case T‑121/23,

Exxonmobil Petroleum & Chemical BVBA, established in Antwerp (Belgium), represented by H. Estreicher, A. Bartl and M. Escorneboueu, lawyers,

applicant,

v

European Commission, represented by K. Mifsud-Bonnici and E. Mathieu, acting as Agents,

and

European Chemicals Agency (ECHA), represented by M. Heikkilä, W. Broere and S. Mahoney, acting as Agents,

defendants,

THE GENERAL COURT (Fifth Chamber),

composed of J. Svenningsen, President, C. Mac Eochaidh and J. Laitenberger (Rapporteur), Judges,

Registrar: V. Di Bucci,

having regard to the written part of the procedure, in particular:

–        the application lodged at the Court Registry on 3 March 2023,

–        the plea of inadmissibility raised by the Commission by separate document lodged at the Court Registry on 30 May 2023,

–        the plea of inadmissibility raised by ECHA by separate document lodged at the Court Registry on 5 June 2023,

–        the applicant’s observations on the pleas of inadmissibility, lodged at the Court Registry on 14 July 2023,

makes the following

Order

1        By its action under Article 263 TFEU, the applicant, Exxonmobil Petroleum & Chemical BVBA, seeks annulment of the letter of the European Commission of 21 December 2022 (‘the contested act’), by which that institution refused to make a request to the European Chemicals Agency (ECHA) to prepare a dossier in accordance with Annex XV to Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC (OJ 2006 L 396, p. 1, corrigendum OJ 2007 L 136, p. 3), for the purposes of re-examining its Decision ED/88/2018 of 19 December 2018, by which that body included phenanthrene on the list of substances identified as being of very high concern provided for in Article 59 of Regulation No 1907/2006 (‘the candidate list’).

 Background to the dispute

2        On 19 December 2018, ECHA issued Decision ED/88/2018.

3        On 21 March 2019, the applicant brought an action for annulment of Decision ED/88/2018 before the Court.

4        The Court dismissed that action by judgment of 9 June 2021, Exxonmobil Petroleum & Chemical v ECHA (T‑177/19, not published, EU:T:2021:336).

5        On 4 April 2022, the European Petroleum Refiners Association (‘Concawe’), of which the applicant is a member, sent the Commission a letter in which it provided various scientific studies and stated the following:

‘Altogether, this information constitutes new, reliable, relevant and decisive data which clearly demonstrate the non-persistent character of phenanthrene in sediment. Given i) the [judgment of 9 June 2021, Exxonmobil Petroleum & Chemical v ECHA (T‑177/19, not published, EU:T:2021:336)] and ii) the new, relevant, reliable and decisive data submitted with this letter, Concawe and its members hereby formally request that the Commission asks ECHA to fully re-examine the identification of phenanthrene as a Substance of Very High Concern in light of the new information which shows that phenanthrene does not meet the criteria for identification as [a very persistent and very bioaccumulative (“vPvB”) substance] under [Regulation No 1907/2006]. Concawe understands that the Commission would initiate this request for ECHA’s re-examination of the identification of phenanthrene under Article 59 of [Regulation No 1907/2006].’

6        On 5 August 2022, the Commission sent a letter to ECHA in which it provided the scientific studies referred to in the previous paragraph and which stated the following:

‘The Commission would … like to consult ECHA for an assessment of the submitted information and, in accordance with Article 77(1) of [Regulation No 1907/2006], asks ECHA to investigate whether the attached information constitutes indeed new, reliable and relevant scientific information that, in a weight of evidence approach, raises doubt about the … identification of phenanthrene [as a substance of very high concern (“SVHC”)]. … Based on this assessment, the Commission will decide on the appropriate next steps to follow, including the possibility of requesting ECHA to prepare a dossier that conforms to the provisions of … Article 59 [of Regulation No 1907/2006] that takes into account an updated body of evidence.’

7        On 4 November 2022, the Secretariat of ECHA sent a letter to the Commission (‘the ECHA report’) in which it stated that it had made an assessment of the new information and ‘conclud[ed] that the new information provided by [Concawe] … [did] not impact the earlier assessment made by ECHA [(Member State Committee)] on the [very persistent] properties of the substance and would not give any grounds for revisiting the identification of phenanthrene as an SVHC due to its vPvB properties’.

8        On 21 December 2022, the Commission sent the contested act to Concawe, to which it annexed the ECHA report. In particular, it stated that, given ECHA’s conclusions, ‘the Commission services consider there is no need to discuss necessary steps to remove phenanthrene from the [candidate list]’.

 Forms of order sought

9        The applicant claims that the Court should:

–        annul the contested act;

–        order the Commission and ECHA to pay the costs.

10      The Commission contends that the Court should:

–        dismiss the action as inadmissible;

–        order the applicant to pay the costs.

11      ECHA contends that the Court should:

–        declare the action inadmissible;

–        order the applicant to pay the costs.

 Law

12      Under Article 130(1) and (7) of the Rules of Procedure of the General Court, the Court may give a decision on inadmissibility without going to the substance of the case if a defendant makes an application asking it to do so.

13      In the present case, as the Commission and ECHA have requested a ruling on the inadmissibility of the action, the Court, finding that it has sufficient information from the documents in the case file, has decided to give a ruling on that request without taking further steps in the proceedings.

14      In support of their pleas of inadmissibility, the Commission and ECHA submit, inter alia, that the action must be dismissed as inadmissible in so far as the contested act is not a challengeable act.

15      By contrast, the applicant claims that the contested act is a challengeable act.

16      First, it maintains that the contested act is not a preparatory measure, but that it lays down the definitive position of the Commission and ECHA.

17      According to the applicant, ECHA de facto re-evaluated the inclusion of phenanthrene in the candidate list, in the light of the information provided by Concawe, which ECHA found to be new, relevant and reliable, but concluded that that information would not support the removal of the substance at issue from the list in question. Thus, the applicant claims that the assessment carried out by ECHA amounts to a decision under Article 59 of Regulation No 1907/2006, which ECHA is competent to adopt only on condition that the Member State Committee reaches a unanimous agreement. However, according to the applicant, ECHA issued that decision without following the procedure set out in Article 59 of Regulation No 1907/2006. The applicant thus claims that the contested act lays down the definitive and unequivocal decision of the Commission and ECHA to refuse to remove phenanthrene from the candidate list, on the basis of the specific evidence submitted by Concawe. Accordingly, no further decision can be expected from them following the issuance of the contested act.

18      Furthermore, although the applicant does not call into question the possibility that, in the future, the classification of phenanthrene could be revised on the basis of new evidence, it nevertheless submits that, by the effects of the contested act, that classification cannot be revised exclusively on the basis of the new evidence submitted by Concawe, as it would, precisely, no longer be new.

19      Secondly, the applicant submits that the contested act is binding on third parties. It states that the maintained obligation to provide a safety data sheet is not a result of Decision ED/88/2018, but of the contested act. That act is, in essence, a new decision taken in the light of the evidence provided by Concawe and concluding that phenanthrene should remain on the candidate list.

20      Thirdly, the applicant claims that the contested act produces legal effects distinct from Decision ED/88/2018 in so far as that act constitutes a reply to a request submitted by Concawe, in which substantial new facts were brought to the attention of the Commission and ECHA.

21      Fourthly, the applicant submits that it had a procedural right to seek reconsideration of Decision ED/88/2018. Thus, its states that, first, in paragraph 115 of the judgment of 9 June 2021, Exxonmobil Petroleum & Chemical v ECHA (T‑177/19, not published, EU:T:2021:336), the Court ruled that ECHA can and, where necessary, must carry out a re-examination on the basis of new, relevant information and that, secondly, there are no limitations as to who may provide such new information. The obligation to take into consideration new evidence is thus, according to the applicant, the source of a procedural right for it, as well as for anyone who would submit new evidence meeting the above standard. The applicant asserts that the very existence of such a procedural right is demonstrated by the fact that the Commission agreed to examine the new evidence in view of a reconsideration of Decision ED/88/2018.

22      It is necessary to examine whether the contested act constitutes a challengeable act.

 The claim for annulment of the contested act

 Preliminary observations

23      In the first place, it should be observed that no provision of Regulation No 1907/2006 specifies the procedure for re-examining a substance that has previously been included in the candidate list if, on the basis of new data, the criteria set out in Article 57 of Regulation No 1907/2006 are no longer satisfied for that substance.

24      Although Regulation No 1907/2006 does not contain express provisions concerning the possibility of re-examining the inclusion of a substance in the candidate list under Article 59 of Regulation No 1907/2006, it should be recalled that any decision adopted on the basis of that provision can, as a general rule, be re-examined in the light of new information available without any express provision being required. In that regard, it should be observed that Article 58(8) of Regulation No 1907/2006 provides that substances included in Annex XIV to that regulation may be removed therefrom where, as a result of new information, they no longer meet the criteria of Article 57 of that regulation. That provision presupposes that ECHA can and, where necessary, must carry out a re-examination on the basis of new, relevant information. Given that the identification of a substance under Articles 57 and 59 of Regulation No 1907/2006 is carried out with a view to the eventual inclusion thereof in Annex XIV, the right and, where appropriate, the obligation to carry out a re-examination on the basis of new information applies a fortiori, inter alia also during the period between, first, the identification of a substance under Article 57 of Regulation No 1907/2006 and its inclusion in the candidate list and, secondly, the subsequent inclusion in Annex XIV. Consequently, any new information arising from a study that was still ongoing at the time of the identification of a substance as being of very high concern is therefore likely to be taken into account, where appropriate, even after the identification laid down in Articles 57 and 58 of Regulation No 1907/2006, and before the subsequent inclusion of that substance in Annex XIV (judgments of 16 December 2020, PlasticsEurope v ECHA, T‑207/18, EU:T:2020:623, paragraphs 53 and 54, and of 9 June 2021, Exxonmobil Petroleum & Chemical v ECHA, T‑177/19, not published, EU:T:2021:336, paragraphs 114 and 115).

25      It is also apparent from the case-law that there is a general principle of law that, in principle, a body which has power to adopt a particular legal measure also has power to abrogate or amend it by adopting an actus contrarius, unless such power is expressly conferred upon another body (judgment of 20 November 2002, Lagardère and Canal+ v Commission, T‑251/00, EU:T:2002:278, paragraph 130).

26      In accordance with the rule of parallelism of procedural requirements and of the actus contrarius, an amendment to a decision must take place in the same way as the initial decision (judgment of 14 December 2006, Gagliardi v OHIM – Norma Lebensmittelfilialbetrieb (MANŪ MANU MANU), T‑392/04, not published, EU:T:2006:400, paragraph 53).

27      In the second place, it should be recalled that, according to settled case-law, only measures the legal effects of which are binding on, and capable of affecting the interests of, the applicant by bringing about a distinct change in his or her legal position are acts or decisions which may be the subject of an action for annulment (see judgments of 12 September 2006, Reynolds Tobacco and Others v Commission, C‑131/03 P, EU:C:2006:541, paragraph 54, and of 13 October 2011, Deutsche Post and Germany v Commission, C‑463/10 P and C‑475/10 P, EU:C:2011:656, paragraph 37). In order to determine whether the contested act produces binding legal effects, it is necessary to examine the substance of that act and to assess those effects on the basis of objective criteria, such as the content of that act, taking into account, as appropriate, the context in which it was adopted and the powers of the institution which adopted the act (see judgment of 20 February 2018, Belgium v Commission, C‑16/16 P, EU:C:2018:79, paragraph 32 and the case-law cited).

28      Furthermore, an act of the Commission which amounts to a rejection must be appraised in the light of the nature of the request to which it constitutes a reply (see order of 13 March 2007, Arizona Chemical and Others v Commission, C‑150/06 P, not published, EU:C:2007:164, paragraph 22 and the case-law cited). In particular, a refusal constitutes an act in respect of which an action for annulment may be brought under Article 263 TFEU provided that the act which the institution refuses to adopt could itself have been contested under that provision (see judgment of 22 October 1996, Salt Union v Commission, T‑330/94, EU:T:1996:154, paragraph 32 and the case-law cited).

29      It is in the light of those considerations that the Court must examine whether the contested act constitutes a challengeable act.

 The existence of a refusal to adopt a challengeable act

30      It should be noted that, as regards the content of the contested act, the Commission stated that its services had considered, on the basis of an ECHA report, that ‘there [was] no need to discuss necessary steps to remove phenanthrene from the [candidate list]’.

31      The contested act follows a request made by Concawe to the Commission that, in the light of new information, the latter ask ECHA to re-examine in full the identification of phenanthrene as a substance of very high concern in accordance with the procedure laid down in Article 59 of Regulation No 1907/2006.

32      It follows that the contested act consists in a refusal by the Commission to initiate the procedure laid down in Article 59(2) of Regulation No 1907/2006.

33      In the light of the case-law cited in paragraph 28 above, the contested act could therefore constitute a challengeable act only if the request which the Commission has the ability to submit to ECHA, under Article 59(2) of Regulation No 1907/2006, could also be the subject of an action for annulment.

34      In that regard, in the first place, the contested act, in so far as it refers to the ‘necessary steps to remove phenanthrene from the [candidate list]’, shows that the Commission did not consider it necessary to adopt a measure at the beginning of the procedure laid down in Article 59(2) of Regulation No 1907/2006.

35      In the second place, it should be pointed out that, under the rule of parallelism of procedural requirements referred to in paragraph 26 above, if a substance no longer meets the criteria set out in Article 57 of Regulation No 1907/2006, the procedure described in Article 59 of Regulation No 1907/2006 must be followed in order to remove it from the list.

36      In that regard, first of all, it is apparent from Article 59(2) and (3) of Regulation No 1907/2006 that the procedure for the identification of substances of very high concern and for the inclusion of those substances in the candidate list begins either by a request from the Commission to ECHA to prepare a dossier in accordance with Annex XV to that regulation, or as a result of the preparation of a dossier by a Member State in accordance with that annex.

37      Next, pursuant to Article 59(4) of Regulation No 1907/2006, the Annex XV dossier is to be published on the ECHA website with a deadline for submitting comments.

38      Lastly, according to Article 59(6) to (8) of Regulation No 1907/2006, if ECHA does not receive or make any comments, it is to include that substance in the candidate list. By contrast, where comments have been received or made, ECHA is to refer the dossier to the Member State Committee. In that regard, if, within 30 days of the referral, the Member State Committee reaches a unanimous agreement on the identification of a substance as being of very high concern, ECHA is to include the substance concerned in the candidate list. Otherwise, the Commission is to prepare a draft proposal on the identification of the substance within three months of receipt of the opinion of the Member State Committee. A final decision on the identification of the substance as being of very high concern is then to be taken by the Commission in accordance with the regulatory procedure with scrutiny provided for in Article 5a of Council Decision 1999/468/EC of 28 June 1999 laying down the procedures for the exercise of implementing powers conferred on the Commission (OJ 1999 L 184, p. 23), as amended.

39      It follows that the request, which the Commission has the ability to submit to ECHA, under Article 59(2) of Regulation No 1907/2006, does not constitute a challengeable act, by reason of the fact that it is prior to the preparation, by that agency, of a dossier in accordance with Annex XV to that regulation and therefore to the implementation of the re-examination procedure resulting from the rule of parallelism of procedural requirements and of the actus contrarius, which, moreover, the applicant does not dispute.

40      Therefore, the contested act consists in a refusal to adopt an act that is not open to challenge for the purposes of Article 263 TFEU.

41      In the third place, that conclusion is not called into question by the applicant’s claim that the assessments made in the contested act are definitive.

42      In that regard, first, the applicant’s assertion that the Commission and ECHA de facto adopted a decision to re-examine Decision ED/88/2018 is unfounded. The Commission merely consulted ECHA, as it was entitled to do, on the information submitted by Concawe, in accordance with Article 77(1) of Regulation No 1907/2006. In so doing, the Commission and ECHA did not therefore in any way conduct, implicitly or explicitly, a re-examination of Decision ED/88/2018, which must be conducted in accordance with the procedure set out in Article 59 of Regulation No 1907/2006. The contested act thus merely constitutes a refusal by the Commission to make a request to ECHA to prepare a dossier in accordance with Annex XV to that regulation. On that point, the Commission has, under Article 59(2) of Regulation No 1907/2006, the option of making or not making such a request to ECHA, which is a prior procedural act and which, in the present case, precedes a re-examination of Decision ED/88/2018.

43      Moreover, contrary to what the applicant claims, the contested act, adopted by the Commission, does not create any legal effects distinct from Decision ED/88/2018, adopted by ECHA, since the contested act in no way replaces Decision ED/88/2018, which therefore continues to produce its own effects.

44      Secondly, it should be noted that the Commission is not itself empowered to re-examine an ECHA decision to include a substance in the candidate list.

45      According to Article 59 of Regulation No 1907/2006, expressly referred to by Concawe in its request for re-examination, the Commission is only empowered to make a request to ECHA to prepare a dossier, in accordance with the relevant sections of Annex XV to that regulation, with a view to identifying, in accordance with the procedure laid down in paragraphs 2 to 10 of that article, substances meeting the criteria set out in Article 57 of that regulation and establishing a candidate list for eventual inclusion in Annex XIV to that regulation.

46      Thirdly, the applicant’s argument, referred to in paragraph 18 above, that the information that it submitted to the Commission for review could no longer be regarded as new cannot succeed. The Commission did not carry out a review in the present case and was not entitled to do so. Furthermore, the novelty of the information submitted by the applicant with a view to requesting once more a review should be assessed solely in the light of the information that was taken into account for the purposes of the adoption of Decision ED/88/2018, that is to say when phenanthrene was included in the candidate list of substances.

47      Consequently, irrespective of the fact that the contested act precludes the initiation of the re-examination procedure, the response that it contains consists in a refusal to adopt an act that is not open to challenge and that is based on assessments that are not definitive. The contested act cannot therefore, as such, be the subject of an action for annulment.

 The existence of possible procedural rights granted to the applicant

48      It should be borne in mind that, according to the case-law, where a provision confers on certain persons the right to make a request to the Commission to initiate a procedure, in particular with a view to adopting an act, or where it provides that those persons enjoy procedural safeguards during such a procedure, the Commission’s refusal to initiate that procedure constitutes a challengeable act. That refusal brings an end to the procedure initiated by the persons in question on the basis of that provision. Such a refusal expresses the Commission’s definitive position and produces binding legal effects and may therefore be the subject of an action for annulment (see order of 8 April 2021, CRII-GEN and Others v Commission, T‑496/20, not published, EU:T:2021:179, paragraph 26 and the case-law cited).

49      It is therefore necessary, in the present case, to examine whether, in the context of the procedure described in Article 59 of Regulation No 1907/2006, the applicant was entitled to submit to the Commission a request for it to initiate the procedure, so that the refusal to initiate that procedure would constitute the adoption of a definitive position by the Commission producing binding legal effects vis-à-vis the applicant within the meaning of the case-law referred to in the previous paragraph.

50      In the first place, it is not apparent from the wording of Article 59(2) of Regulation No 1907/2006 that the EU legislature intended to confer on individuals, such as the applicant, the right to request the initiation of the procedure for including a substance in the candidate list or the right to request a re-examination of that inclusion.

51      According to that provision, only a Member State or ECHA, at the request of the Commission, may submit a dossier drawn up in accordance with Annex XV in order to propose that a substance be identified as being of very high concern and included in the candidate list.

52      Thus, under the rule of parallelism of procedural requirements mentioned in paragraph 26 above, only a Member State or ECHA, at the request of the Commission, may submit a dossier drawn up in accordance with Annex XV in order to propose that the inclusion of a substance in the candidate list be re-examined.

53      By contrast, the rule of parallelism of procedural requirements cannot justify the grant of a subjective right, to the applicant or to Concawe, to require the Commission to make a request to ECHA to prepare a dossier in accordance with Annex XV or to require a Member State to prepare such a dossier.

54      It follows that Article 59 of Regulation No 1907/2006 cannot constitute the basis of a request by a natural or legal person to compel the Commission to make a request to ECHA to prepare a dossier in accordance with Annex XV and therefore that the applicant has no right to require the Commission to make a request to ECHA to prepare and submit a dossier in accordance with Annex XV.

55      Contrary to what the applicant claims, that conclusion is not invalidated by paragraph 115 of the judgment of 9 June 2021, Exxonmobil Petroleum & Chemical v ECHA (T‑177/19, not published, EU:T:2021:336), which states that ECHA can and, where necessary, must carry out a re-examination on the basis of new, relevant information.

56      Paragraph 115 of the judgment of 9 June 2021, Exxonmobil Petroleum & Chemical v ECHA (T‑177/19, not published, EU:T:2021:336), merely provides, first, that, in the absence of a dossier prepared in accordance with Annex XV, re-examination on the basis of new and relevant information is a possibility for ECHA and, in particular, its Member State Committee, and, secondly, that such a re-examination is obligatory if, where necessary, a dossier is prepared in accordance with Annex XV by ECHA or a Member State.

57      Thus, the judgment of 9 June 2021, Exxonmobil Petroleum & Chemical v ECHA (T‑177/19, not published, EU:T:2021:336), does not recognise any procedural right in favour of individuals allowing them to require the Commission to submit a request to ECHA under Article 59(2) of Regulation No 1907/2006. It is for the Commission or the Member States alone to examine whether to make such a request.

58      In the second place, it is true that Article 59(4) of Regulation No 1907/2006 states that, following the publication on its website of a notice that an Annex XV dossier has been prepared for a substance, interested parties are to be invited to submit comments to ECHA on the Annex XV dossier.

59      However, it has already been held that Article 59(4) of Regulation No 1907/2006 did not guarantee a right to be heard to interested parties. That provision merely provides for a public consultation that does not confer on interested parties any specific procedural right other than the right to submit comments. Thus, ECHA is not required, under that provision, to hear an individual who might be affected by the decision taken at the end of the administrative procedure (see, to that effect, judgment of 9 June 2021, Exxonmobil Petroleum & Chemical v ECHA, T‑177/19, not published, EU:T:2021:336, paragraphs 243 and 244).

60      In any event, first, the applicability of Article 59(4) of Regulation No 1907/2006 presupposes, according to the very wording of that provision, that an Annex XV dossier has been prepared by ECHA at the request of the Commission or by a Member State. However, that is not the case here.

61      Secondly, an operator who wishes to have a substance removed from the candidate list and who, to that end, contacts the Commission or a Member State, must submit its observations to that institution or to the Member State concerned on the data that, in its view, justify that removal.

62      It follows that Article 59(4) of Regulation No 1907/2006 contains no procedural safeguard such as to render the present action admissible.

63      According to the applicant, such a conclusion is precluded by the fact that the refusal or a request for re-examination of the inclusion of a substance in the candidate list constitutes, even if only de facto, a decision to maintain that substance on the candidate list. If it were not possible to challenge such a decision, the producers, suppliers and users of the substance concerned would be deprived of effective judicial protection.

64      On that point, it should be noted that, if it were to be accepted, the applicant’s argument would amount to the creation of an unprecedented procedure by case-law. Having regard to the principles of institutional balance and conferral of powers, as enshrined in Article 13(2) TEU (see, to that effect, judgment of 25 October 2017, Commission v Council (WRC‑15), C‑687/15, EU:C:2017:803, paragraph 40 and the case-law cited), the Court does not have the power to adjust the provisions of Regulation No 1907/2006.

65      In the absence, as the law currently stands, of a specific provision in Regulation No 1907/2006, the Commission or the Member States are the only ones empowered to initiate or not to initiate the procedure for re-examining the inclusion of a substance in the candidate list, which precludes the right of a natural or legal person to require them to adopt a position on their request for re-examination or, where such a position has been adopted by the Commission, to bring an action for annulment.

66      In that regard, the fact that the Commission did not reject, without a prior examination, the information provided by the applicant, but that, in the interests of diligence, it consulted ECHA on the basis of Article 77 of Regulation No 1907/2006 concerning that information, cannot have the effect of compelling that institution to make a request to ECHA to prepare and to submit a dossier in accordance with Annex XV.

67      The application for annulment of the contested act is therefore dismissed as inadmissible.

 The ECHA report

68      In so far as the applicant also seeks the annulment of the ECHA report considered in isolation, which is not expressly apparent from its written pleadings, it should be noted that that report is not a challengeable act pursuant to Article 263 TFEU.

69      First, that report merely provides scientific and technical advice requested by the Commission in accordance with Article 77(1) of Regulation No 1907/2006, which stipulates that ECHA is to provide the EU institutions with the best possible scientific and technical advice on questions which are referred to it and which fall within its remit. Article 77(1) of Regulation No 1907/2006 does not limit the scope of those requests in so far as they concern chemicals and fall within the remit of ECHA, which is indeed the case here. In addition, the scope of the Commission’s request was indeed clarified in the Commission’s letter of 5 August 2022. The applicant is therefore wrong to assert that Article 77(2) of Regulation No 1907/2006, which sets out the tasks of the Secretariat of ECHA, precludes a referral to ECHA in a situation such as that in the present case.

70      Secondly, it should be noted that, in its report, ECHA issues a technical and scientific opinion that is not binding on the Commission and that is intended to assist the Commission in adopting a measure that has no binding legal effects such as to affect the interests of the applicant. It is in that context that, in its request to ECHA of 5 August 2022, the Commission stated that, based on that agency’s assessment, it would decide on the appropriate next steps to follow (see paragraph 6 above).

71      Thirdly, for reasons similar to those set out in paragraphs 41 to 46, the ECHA report does not definitively establish that agency’s position. If a Member State were to prepare a dossier in accordance with Article XV or if the Commission were to make a request to ECHA to prepare such a dossier, that agency would have to process such dossiers pursuant to Article 59 of Regulation No 1907/2006. In that context, the ECHA report, called into question by the applicant, is not binding on that agency and, in particular, on its Member State Committee.

72      It follows that the action must be dismissed as inadmissible for lack of a challengeable act.

 Costs

73      Under Article 134(1) of the Rules of Procedure, the unsuccessful party is to be ordered to pay the costs if they have been applied for in the successful party’s pleadings. Since the applicant has been unsuccessful, it must, in accordance with the forms of order sought by the Commission and ECHA, be ordered to bear its own costs and to pay the costs incurred by those parties.

On those grounds,

THE GENERAL COURT (Fifth Chamber)

hereby orders:

1.      The action is dismissed as inadmissible.

2.      Exxonmobil Petroleum & Chemical BVBA shall bear its own costs and pay those incurred by the European Commission and the European Chemicals Agency (ECHA).

Luxembourg, 22 December 2023.

*      Language of the case: English.

© European Union
The source of this judgment is the Europa web site. The information on this site is subject to a information found here: Important legal notice. This electronic version is not authentic and is subject to amendment.